Monocyte Adherence Induced by Lipopolysaccharide Involves CD14, LFA-1, and Cytohesin-1
REGULATION BY Rho AND PHOSPHATIDYLINOSITOL 3-KINASE*

Zakaria HmamaDagger §, Keith L. KnutsonDagger , Patricia Herrera-VelitDagger , Devki NandanDagger , and Neil E. ReinerDagger parallel

From Dagger  Department of Medicine (Division of Infectious Diseases) and the  Department of Microbiology and Immunology, The University of British Columbia, Faculties of Medicine and Science, The Research Institute of the Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia V5Z 3J5, Canada and § The Laboratoire d'Immunologie, Faculté des Sciences Dhar Mahraz, Université Mohamed Ben Abdallah, BP 1796, Atlas Fés, Morocco

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Mechanisms regulating lipopolysaccharide (LPS)-induced adherence to intercellular adhesion molecule (ICAM)-1 were examined using THP-1 cells transfected with CD14-cDNA (THP-1wt). THP-1wt adherence to ICAM-1 was LPS dose-related, time-dependent, and inhibited by antibodies to either CD14 or leukocyte function associated antigen (LFA)-1, but was independent of any change in the number of surface expressed LFA-1 molecules. A potential role for phosphatidylinositol (PI) 3-kinase (PI 3-kinase) in LPS-induced adherence was examined using the PI 3-kinase inhibitors LY294002 and Wortmannin. Both inhibitors selectively attenuated LPS-induced, but not phorbol 12-myristate 13-acetate-induced adherence. Inhibition by these agents was unrelated to any changes in either LPS binding to or LFA-1 expression by THP-1wt cells. LPS-induced adherence was also abrogated in U937 cells transfected with a dominant negative mutant of of PI 3-kinase. Toxin B from Clostridium difficile, an inhibitor of the Rho family of GTP-binding proteins, abrogated both PI-3 kinase activation and adherence induced by LPS. Cytohesin-1, a phosphatidylinositol 3,4,5-triphosphate-regulated adaptor molecule for LFA-1 activation, was found to be expressed in THP-1wt cells. In addition, treatment of THP-1wt with cytohesin-1 antisense attenuated LPS-induced adherence. These findings suggest a model in which LPS induces adherence through a process of "inside-out" signaling involving CD14, Rho, and PI 3-kinase. This converts low avidity LFA-1 into an active form capable of increased binding to ICAM-1. This change in LFA-1 appears to be cytohesin-1-dependent.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Adherence of monocytes to endothelial cells is an essential requirement for the localization of these cells to sites of tissue inflammation (1-3). Several reports have shown that this process is dependent upon the monocyte surface molecule lymphocyte function-associated antigen-1 (LFA-1)1 (CD11a/CD18; alpha Lbeta 2) (Refs. 3-5 and reviewed in Refs. 6 and 7). Intercellular adhesion molecule-1 (ICAM-1) (CD54) has been identified as a high affinity counter-receptor for LFA-1 (8). Interactions of ICAM-1 with LFA-1 mediate several important functions in the immune system in addition to adherence (6). The basal affinity of LFA-1 for ICAM-1 or its other ligands is low and LFA-1 must be activated to mediate stable adhesion (4, 5). Indeed, in its activated form, the affinity of LFA-1 for ICAM-1 increases 200-fold in comparison with its affinity in the resting state (9). This is consistent with a process of "inside-out" signaling that converts LFA-1 into an activated form capable of mediating increased adhesion. It is important to note that conditions which give rise to increased adherence do not necessarily lead to increased cell surface expression of LFA-1 (5, 10).

The signaling events that link cell stimulation to the activation of LFA-1 are incompletely understood. Recently, a regulatory protein that interacts with the cytoplasmic tail of CD18 has been cloned (11). This protein, cytohesin-1, contains a pleckstrin homology domain that binds the phosphatidylinositol 3-kinase (PI 3-kinase) metabolite, phosphatidylinositol 3,4,5-triphosphate (PtdIns-3,4,5-P3), leading to changes in properties of the protein (12). These findings suggest a potential role for PI 3-kinase in regulating the activity of LFA-1.

Bacterial lipopolysaccharide (LPS) is known to enhance the accumulation of leukocytes at inflammatory foci (13) and the adherence of leukocytes to endothelial cells in vitro (14, 15). Although it has also been shown that LPS-induced adherence is mediated at least in part by LFA-1 (16), the pathway linking LPS to LFA-1 has not been characterized. A dominant LPS signaling pathway involves the membrane receptor CD14 (17, 18). Binding of LPS to CD14 results in the activation of multiple Src family protein tyrosine kinases, and this appears to involve the physical association of p53/p56lyn with the receptor (19). It has also been shown that LPS induces the CD14-dependent association of an activated form of PI 3-kinase with p53/p56lyn (20). Furthermore, activation of monocyte PI 3-kinase by LPS results in the generation of PtdIns-3,4,5-P3 (21), which as discussed above is known to regulate various effector functions including cell adhesion (22, 23). Taken together, these findings suggest the possibility that LPS-induced adhesion may be mediated through a pathway involving PI 3-kinase leading to changes in LFA-1 activity. The results of the present study show that LPS binding to CD14 induces monocyte adherence dependent upon LFA-1, ICAM-1, and cytohesin-1, via a PI 3-kinase-dependent pathway regulated by the small GTP-binding protein Rho.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Reagents and Chemicals-- RPMI 1640, Hanks' balanced salt solution (HBSS), and penicillin/streptomycin were from Stem Cell Technologies (Vancouver, British Columbia). Human AB+ serum was provided by The Canadian Red Cross (Vancouver, British Columbia). LPS from Escherichia coli O127:B8 was from Difco. LPS was labeled with FITC as described (24, 25). Purified soluble, recombinant ICAM-1 (sICAM-1) was a generous gift from Dr. J. R. Woska, Jr. (Boehringer Ingelheim, Ridgefield, CT). Phorbol 12-myristate 13-acetate (PMA), wortmannin, L-alpha -phosphatidyl-L-serine), L-alpha -phosphatidylinositol (PtdIns), and L-alpha -phosphatidylinositol 4,5-diphosphate were purchased from Sigma. LY294002 was from Calbiochem. Toxin B purified from Clostridium difficile was generously provided by Dr. G. Armstrong (University of Alberta, Edmonton, Alberta). Protein A-agarose, and electrophoresis reagents were purchased from Bio-Rad. [gamma -32P]ATP was from Amersham International (Oakville, Ontario, Canada).

Monoclonal Antibodies (mAbs)-- The following mAbs were used: 3C10 (IgG2b, anti-CD14 mAb, a gift from Dr. W. C. Van Voorhis, University of Washington, Seattle, WA), W6/32 (IgG2a, anti-HLA-class I, American Type Culture Collection, Manassas, VA), TS1/18 (IgG1, anti-CD18), and TS1/22 (IgG1, anti-CD11a) were from the Hybridoma Bank of the University of Iowa, Iowa city, IA. Anti-PI 3-kinase mAb was from Upstate Biotechnology (Lake Placid, NY).

Cell Lines-- The monocytic cell lines THP-1wt (THP-1 cells stably expressing glycosylphosphatidylinositol-anchored CD14) and THP-1rsv (THP-1 cells transfected with vector alone) were kindly provided by Dr. R. Ulevitch (The Scripps Research Institute, La Jolla, CA). Transfection of the promonocytic cell line U937 with cDNA encoding the entire coding region of either wild-type bovine PI 3-kinase subunit p85alpha (Wp85alpha ) or mutant bovine p85alpha (Delta p85alpha ) was as described (21). The mutant has a deletion of 35 amino acids from residues 479-513 of bovine p85alpha and the insertion of two other amino acids (Ser-Arg) in the deleted position. This alteration prevents the association of mutant p85alpha with the p110 catalytic subunit. Mutant p85alpha competes with native p85 for binding to essential signaling proteins, thereby acting as a dominant negative mutant (21, 26). These transfected cell lines are referred to as Wp85-U937 and Delta p85-U937. All cell lines were cultured in RPMI 1640 supplemented with 10% FCS (Hyclone, Logan, UT), 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100 µg/ml).

Cell Adhesion to Immobilized sICAM-1-- Flat-bottomed, polystyrene, cell culture-treated, microtiter plates (Becton Dickinson, Franklin Lakes, NJ) were loaded with purified sICAM or BSA (coating control) diluted in 0.1 M carbonate buffer (pH 9) for 1 h at 37 °C and then transferred to 4 °C overnight. Wells were then washed with HBSS and blocked with 1% BSA in RPMI 1640 for 1 h at 37 °C. Blocking solution was discarded and 100-µl aliquots of cells (1 × 105) were dispensed into duplicate wells. Plates were incubated for 30 min at 37 °C to allow cell sedimentation prior to treatment with stimuli or inhibitors. Cells were then assayed for adherence at 37 °C. Nonadherent cells were removed by carefully washing three times with 200 µl of warm (37 °C) incubation medium. Adherent cells were then fixed with 2% paraformaldehyde/HBSS. Fixed cells were washed once with HBSS and stained for 10 min with 0.05% crystal violet in 20% methanol. Crystal violet was rinsed out of the wells with water, and the plates were allowed to dry. The dye was then eluted from cells by addition of 100 µl of 100% methanol, and absorbance at 570 nm was immediately recorded in a microtiter plate reader. Adherent cells were quantitated by using a standard curve generated with a range of input cell numbers incubated with PMA (20 ng/ml) for 60 min at 37 °C and fixed without prior washing.

Cell Surface Phenotype Analysis-- To measure the expression of cell surface molecules, cells were incubated with specific mouse mAb (10 µg/ml) for 30 min, then washed twice and labeled with FITC-conjugated F(ab')2 sheep anti-mouse IgG (Sigma) for 30 min. Cells were then washed twice and fixed in 2% paraformaldehyde in staining buffer. All staining and washing procedures were performed at 4 °C in HBSS containing 0.1% NaN3 and 1% FCS. Cell fluorescence was analyzed using a Coulter Elite flow cytometer (Hialeah, FL). Relative fluorescence intensities of 5000 cells were recorded as single-parameter histograms (log scale, 1024 channels, 4 log decades), and the mean fluorescence intensity (MFI) was calculated for each histogram. Results are expressed as specific MFI index, which corresponds to the ratio: MFI of cells + specific antibody/MFI of cells + irrelevant isotype-matched IgG.

In Vitro PI 3-Kinase Assay-- Aliquots of cell lysates adjusted for protein content (300-500 µg of protein) were incubated for 4 h at 4 °C with mAb to PI 3-kinase, and immune complexes were adsorbed onto protein A-agarose for 1 h. The complexes were washed twice with lysis buffer and three times with 10 mM Tris-HCl (pH 7.4). PI 3-kinase activity was measured as described (20). Briefly, immunoprecipitates were incubated for 10 min at 4 °C with 10 µg of sonicated (3 × 20 s in a ultrasonic cell disrupter, Branson Sonic Power Co., Danbury, CT) PtdIns in 10 µl of 30 mM Hepes to which was added 40 µl of kinase buffer (30 mM Hepes, 30 mM MgCl2, 200 µM adenosine, 50 µM ATP, and 10 µCi of [gamma -32P]ATP). Reactions were carried out for 15 min at room temperature and stopped by the addition of 100 µl of 1 N HCl and 200 µl of chloroform:methanol (1:1, v/v). Lipids were separated on oxalate-treated silica TLC plates using a solvent system of chloroform:methanol:water:28% ammonia (45:35:7.5:2.5, v/v/v/v). Plates were exposed to x-ray film at -70 °C. Incorporation of radioactivity into lipids was quantitated by excising the corresponding portions of the TLC plate followed by liquid scintillation counting.

RNA Isolation and RT-PCR-- RNA isolation, cDNA synthesis, and PCR conditions were as described previously (27). Sequences of oligonucleotide primers used in PCR amplifications were as follows: cytohesin-1 sense, CGC GGG GAA TTC GCC ACC ATG GAG GAG GAC GAC AGC TAC GTT CCC; cytohesin-1 antisense, CGC GGG GCG GCC GCT TTA GTG TCG CTT CGT GGA GGA GAC CTT (11); beta -actin sense, CAC CCC GTG CTG CTG ACC GAG GCC; beta -actin antisense, CCA CAC GGA GTA CTT GCG CTC AGG (27). Appropriate negative controls (no DNA and RNA without RT) were included in the RT-PCR experiments.

Sense and Antisense Oligonucleotides-- Phosphorothioate-modified oligonucleotides (S-oligos) to cytohesin-1 were synthesized by Life Technologies, Inc. Twenty one-mer sequences spanning the presumed translation initiation site of human cytohesin-1 cDNA (28) were made in both sense and antisense orientations as follows: sense, 5'-ATG GAG GAG GAC GAC AGC TAC-3'; antisense, 5'-GTA GCT GTC GTC CTC CTC CAT-3'. The sequences were selected by screening for uniqueness using Blast 227 and were also tested for lack of secondary structure and oligonucleotide pairing by using Primer Software (version 2.0, Scientific and Educational Software). THP-1wt cells (106) were incubated for 2 h at 37 °C and 5% CO2 in 250 µl of RPMI 1640 containing 2.5% LipofectAMINE (Life Technologies, Inc.) and various concentrations of S-oligos. After incubation, the medium was adjusted to 1 ml and supplemented with 10% FCS, and cells were cultured for an additional 18 h. Cells were then washed and tested in adhesion assay as described above.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

THP-1 Phenotype Analysis-- Surface expression of CD14 and LFA-1 molecules was analyzed by immunofluorescence and FACS analysis. The representative record shown in Fig. 1 demonstrates that cells transfected with CD14 (THP-1wt) and control cells transfected with vector alone (THP-1rsv) expressed similar levels of both LFA-1 alpha - and beta -chains (CD11a and CD18, respectively). However, THP-1wt cells expressed about 80-fold more CD14 than did THP-1rsv cells.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 1.   CD14 and LFA-1 surface expression on THP-1 cell lines. THP-1rsv and THP-1wt cells were incubated for 30 min at 4 °C with either anti-CD14 (a), anti-CD18 (LFA-1 beta -chain) (b), or anti-CD11a (LFA-1 alpha -chain) (c), then washed twice and labeled with FITC-conjugated F(ab)'2 sheep anti-mouse IgG. Samples were washed twice and fixed in 2% paraformaldehyde before FACS analysis. Results are expressed as histograms of fluorescence intensity (log scale) derived from 5000 events. In each panel, histograms displaced to the right represent cells stained with specific mAbs, and histograms on the left represent cells stained with irrelevant isotype-matched IgG. Numerical values in the top right of each frame indicate the MFI index, which corresponds to the ratio: MFI of cells incubated with specific antibody/MFI of cells stained with irrelevant isotype-matched IgG. The data shown are representative of results obtained in five separate experiments yielding similar results.

Adherence of THP-1 Cells to Immobilized sICAM-1-coated Plates-- Initial experiments were carried out to standardize the model system of LPS-induced adherence of THP-1 cells to sICAM-1. CD14-transfected THP-1wt cells and control THP-1rsv cells were incubated in microtiter wells coated with sICAM-1 at concentrations ranging from 0 to 40 µg/ml and treated with LPS in the presence of 0.5% normal AB+ serum. THP-1wt cells adhered to sICAM-1 in a dose-dependent manner with a maximum of 48 ± 8.7% cells binding to wells coated with 20 µg/ml of sICAM-1 (Fig. 2A). In contrast, control THP-1rsv cells adhered at maximum rate of 8.3 ± 2%. In the absence of sICAM-1, only 4-5% of the THP-1wt cell adhered nonspecifically to the plate (data not shown). Binding specificity for ICAM-1 was also demonstrated by control experiments in which only 4.8 ± 3.2% of THP-1wt cells adhered to wells coated with BSA at 20 µg/ml (n = 4, data not shown).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 2.   THP-1 cell adherence to immobilized sICAM-1. Flat-bottomed, polystyrene cell culture-treated 96-well microtiter plates were loaded with 105 cells/well in 200 µl of RPMI 1640 (final volume), and cells were allowed to adhere at 37 °C in a humidified atmosphere containing 5% CO2. Unbound cells were washed away, and attached cells were fixed with 2% paraformaldehyde/HBSS and stained with 0.05% crystal violet. Excess staining solution was rinsed away, and the absorbance of the dye retained by the adherent cells (eluted by addition of 100% methanol) was measured in individual wells at 570 nm. Duplicate determinations were made for each data point. Adherence was quantitated using a standard curve generated with a range of known input cell numbers. A, adherence of THP-1wt or THP-1rsv cells in response to 2 µg/ml LPS (in presence of 0.5% AB+) assayed for 1 h in wells precoated with a range of concentration of sICAM-1 (0-40 µg/ml). B, THP-1wt cells were stimulated with a range of concentration of LPS (0-10 µg/ml) in presence of 0.5% AB+ serum for 1 h in wells coated with 20 µg/ml of sICAM-1 or BSA. C, adherence of THP-1wt and THP-1rsv cells stimulated with LPS (1 µg/ml in 0.5% AB+ serum) for different times (7 min to 2 h) in wells coated with 20 µg/ml sICAM-1. The values shown in each panel are the averages of two independent determinations obtained in separate experiments.

THP-1wt and THP-1rsv cells were also examined for adherence in the presence of a range (0.1-10 µg/ml) of concentrations of LPS (Fig. 2B). Treatment of THP-1wt cells with LPS resulted in a dose-dependent increase in adherence that was maximal (52.1 ± 6.1%, mean ± S.E., n = 2) at 1 µg/ml. Maximal adherence observed with THP-1rsv was only 10.7 ± 1.8% (mean ± S.E., n = 2), and this was not affected by LPS, indicating that LPS-induced adherence in this system was largely CD14-dependent. In other experiments, cells were incubated with LPS (1 µg/ml in 0.5% AB+ serum) for up to 2 h to determine the time course of THP-1 adherence to sICAM-1 (Fig. 2C). LPS-stimulated adherence was maximal by 60 min and remained stable for the second hour. The importance of serum was also addressed. The results showed that exposure of cells to LPS in the absence of serum resulted in markedly reduced adherence (12.1 ± 0.8%, mean ± S.E., n = 2). Conversely, treatment with serum alone did not induce cell adherence (data not shown).

Cell Surface Molecules Involved in LPS-induced THP-1 Adherence to sICAM-1-- As shown above, only cells transfected with CD14 displayed enhanced adherence in response to LPS. The role of CD14 in cell adherence was investigated further by competitive inhibition with a neutralizing anti-CD14 mAb 3C10 (18, 29). Fig. 3A shows that preincubation of THP-1wt cells with mAb 3C10 prior exposure to LPS led to approximately 80% inhibition of adherence. Competitive inhibition with mAb was also used to examine the extent of involvement of LFA-1 in this model. The results obtained (Fig. 3A) show significant inhibition with either neutralizing anti-CD11a mAb (TS1/18) or anti-CD18 mAb (TS1/22) (30, 31). When a range of concentrations of anti-CD14 and anti-LFA-1 mAbs were tested, a concentration of 10 µg/ml was observed to result in maximal inhibition of LPS-induced adherence (data not shown). Furthermore, when compared with blockade of either CD11a or CD18 alone, inhibition (85%) was enhanced when anti-CD18 and anti-CD11a were used in combination. Specificity of inhibition by anti-CD14 and anti-LFA-1 mAbs was validated using anti-MHC class I mAb, W6/32. Despite its binding to constitutively expressed cell surface molecules, W6/32 did not affect LPS-induced adherence.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of LPS-induced adherence with anti-CD14 and anti-LFA-1 mAbs (A) and effect of LPS on cell surface expression of LFA-1 (B). A, microtiter wells were loaded with THP-1wt cells (1 × 105 in RPMI 1640), and cells were incubated for 30 min at room temperature with either W6/32 (anti-HLA class I), 3C10 (anti-CD14), TS1/18 (anti-LFA-1beta , beta -chain), TS1/22 (anti-LFA-1alpha , alpha -chain), or a mixture (1:1) of TS1/18 and TS1/22 (final concentrations, 10 µg/ml). LPS was then added to a final concentration of 1 µg/ml in 0.5% AB+ serum, and cells were assayed for adherence for 30 min at 37 °C and 5% CO2. Adherent cells were stained with crystal violet, and the absorbances were measured as described in the legend to Fig. 2. Results are expressed as percent of maximal adherence, which corresponds to: absorbance of cells incubated with antibody prior to exposure to LPS/absorbance of cells treated with LPS in the absence of antibody × 100. B, THP-1rsv cells were incubated for 30 min at 37 °C in medium alone (a), in medium plus 1 µg/ml LPS (0.5% AB+ serum) (b), in medium plus 5 µg/ml LPS (0.5% AB+ serum) (c), or in medium plus 5 × 10-7 M fMet-Leu-Phe (d). Cells were washed and stained with either anti-CD11a (LFA-1 alpha -chain) or anti-CD18 (LFA-1 beta -chain) and then with FITC-conjugated F(ab)'2 sheep anti-mouse IgG as described in the legend to Fig. 1. In each panel, histograms displaced to the right represent cells stained with specific mAbs, and histograms on the left represent cells stained with irrelevant isotype-matched IgG. Numerical values in boldface indicate MFI indices calculated as described in the legend to Fig. 1. The data shown in A are means ± S.E. of values obtained in three separate experiments. B shows representative results from one of two separate experiments yielding similar results.

Certain agonists are known to induce increased adherence by either up-regulating integrin expression, by increasing integrin affinity for substrate or by a combination of these effects (32). To address whether the difference observed between THP-1wt and THP-1rsv could be related to altered integrin expression induced by LPS, cell surface expression of CD11a and CD18 was analyzed. As shown in Fig. 3B, LPS treatment did not affect the expression of these proteins by THP-1wt cells. In contrast, incubation of cells with fMet-Leu-Phe, an agonist known to up-regulate integrin expression (33), induced significant increases in expression of both CD11a and CD18. Taken together, these findings suggest that LPS does not modify the number of surface expressed LFA-1 molecules, but rather initiates a signaling sequence through CD14 leading to increased avidity of LFA-1 for ICAM-1.

LPS-induced Adherence Is Phosphatidylinositol 3-Kinase-dependent-- Recent evidence has suggested a role for PI 3-kinase in signaling pathways activated by LPS (20, 21). To examine the potential involvement of PI 3-kinase in LPS-induced adherence, cells were incubated with various concentration of the PI 3-kinase inhibitors wortmannin and LY294002 for 20 min prior to the addition of LPS. Preincubation with wortmannin inhibited LPS-induced adherence in a dose-dependent manner (Fig. 4A, maximum inhibition 92.9 ± 6.7%, mean ± S.E., n = 3) with an IC50 of approximately 1 nM. This value is 10 times lower than the IC50 for wortmannin as determined for inhibition of fMet-Leu-Phe-stimulated neutrophil homotypic aggregation (33). LY294002, an inhibitor of PI 3-kinase that acts via a distinct mechanism, when used at concentrations known to be relatively selective for inhibition of PI 3-kinase, also attenuated LPS-induced adherence (Fig. 4B, maximum inhibition 89.5 ± 2.1%, mean ± S.E., IC50 ~0.45 µM, n = 3). In contrast to abrogation of LPS-induced adherence, neither wortmannin nor LY294002 had significant effects on PMA-induced adherence, except at high concentrations. These results show that inhibition of LPS-induced adherence by wortmannin or LY294002 is not due to nonspecific toxicity. Moreover, they suggest that the pathways regulating adherence in response to PMA and LPS are distinct.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Wortmannin and LY294002 attenuate LPS-induced adherence. 1 × 105 THP-1wt cells (in 200 µl of RPMI 1640, final volume) were dispensed into 96-well microtiter plates and incubated for 20 min at 37 °C and 5% CO2 with various concentrations of wortmannin (0-100 nM) (A) or LY294002 (0-32 µM) (B). Either LPS (1 µg/ml in 0.5% AB+ serum) or PMA (20 ng/ml) were then added for 60 min at 37 °C. Adherent cells were stained with crystal violet, and absorbances were measured as described in the legend to Fig. 2. Duplicate determinations were made for each data point. The data are presented as percent of maximal adherence, calculated as described in the legend to Fig. 3. In C, cells were incubated for 20 min in RPMI 1640 alone (A), in RPMI 1640 plus 100 nM wortmannin (B), or in RPMI 1640 + 16 µM LY294002. Cells were then washed and stained for CD11a and CD18 as described in the legend to Fig. 1. Results are expressed as histograms of fluorescence intensity and MFI indices as described in the legend to Fig. 1. In A and B the values shown are the averages of two independent determinations obtained in separate experiments. C shows results obtained in one of two independent experiments that yielded similar results.

PI 3-kinase inhibitors have been shown to affect the expression of some cell surface receptors (34). Experiments were done, therefore, to examine the effects of wortmannin and LY294002 on the expression of CD11a and CD18. The data shown in Fig. 4C indicate that high concentration of inhibitors (100 nM wortmannin and 16 µM LY294002) resulted in only small changes (20-30% reductions) in surface expression of CD18 and CD11a. These modest changes appear insufficient to explain the marked attenuation of LFA-1-mediated adherence to sICAM-1. Binding of LPS to cells was also examined using FITC-LPS and FACS analysis. LPS binding was not altered in THP-1wt cells pretreated with either wortmannin or LY294002 (data not shown).

The requirement for PI 3-kinase in LPS-induced adherence was also examined in cells transfected with a dominant negative mutant of p85 (Delta p85). Stable transfection with Delta p85 resulted in a significant reduction in LPS-stimulated PI 3-kinase activity (Fig. 5A), and this correlated with marked attenuation of cell adherence to sICAM-1 (Fig. 5B). In contrast, cells transfected with wild-type p85 showed both LPS-stimulated PI 3-kinase activity and adherence. Taken together, these findings suggest that PI 3-kinase activation plays a central role in LPS-induced adherence.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   PI 3-kinase activity and adherence of U937 cells transfected with either wild-type bovine p85alpha or dominant negative mutant Delta p85alpha . A, cells were stimulated with either 1 µg/ml LPS or medium alone followed by detergent lysis and immunoprecipitation with anti-PI 3-kinase antibody. Phosphatidylinositol kinase activity was assayed as described under "Experimental Procedures." Radioactivity observed at the origin (ORI) reflects residual, water-soluble 32P-labeled material in the samples. Spots corresponding to phosphatidylinositol phosphate (PIP) were cut and analyzed by scintillation counting. Activities, expressed as percent of control (untreated) cells transfected with wild-type p85alpha , are shown at the top of the figure. B, 1 × 105 cells of either p85alpha or Delta p85alpha transfected U937 cells were exposed to LPS (indicated concentration) in the presence of 0.5% AB+ and allowed to adhere to either BSA or sICAM-1 for 60 min at 37 °C and 5% CO2. Unbound cells were washed away, and adherence was assayed as described in the legend to Fig. 2. The data shown in A are the means ± S.E. of values obtained in three separate experiments. Results in B are from one of two independent experiments that yielded similar results.

Rho Regulates PI 3-Kinase Activation and LPS-induced Adherence-- Small GTP-binding proteins of the Rho family participate in various important signaling pathways, including those regulating cellular adhesion (35-37). C. difficile toxin B, which specifically inhibits Rho proteins (38, 39), was used to investigate the potential role of Rho in the regulation of LPS-induced adherence. Pretreatment for 30 min with 2 nM toxin B resulted in significant and maximal attenuation of LPS-induced adherence of THP-1wt to sICAM-1 (Fig. 6A) (63.5 ± 5.0% inhibition, mean ± S.E., n = 3). In contrast, induction of adherence in response to PMA was toxin-resistant. To analyze further the inhibitory effect of toxin B, a dose response analysis was performed. Three separate experiments showed that IC50 for toxin inhibition of LPS-induced adherence was ~4 nM and that 20 nM produced maximal inhibition (86.0 ± 2.8% inhibition, mean ± S.E., n = 3). In contrast, maximal inhibition of PMA-induced adherence was less than 20%. To address whether Rho regulates activation of PI 3-kinase in response to LPS, cells were incubated with toxin B under the same experimental condition as those used for adherence and then stimulated with LPS for 20 min. The data shown in Fig. 6C indicate that toxin B reduced LPS-induced PI 3-kinase activity in a dose-dependent manner.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   C. difficile toxin B attenuates both LPS-induced adherence and PI 3-kinase activation. 1 × 105 THP-1wt cells were dispensed into sICAM-1-coated microtiter wells and incubated at 37 °C and 5% CO2 with 2 nM of toxin for the times indicated (A) or for 30 min with various toxin concentrations (B). LPS (1 µg/ml in 0.5% AB+ serum) or PMA (20 ng/ml) were then directly added to the wells for 30 min at 37 °C. Adherent cells were assayed as described in the legend to Fig. 2, and data are presented as percent of maximal adherence, calculated as described in the legend to Fig. 3. In C, cells pretreated with toxin B (indicated concentrations for 30 min) were stimulated with 1 µg/ml LPS in 0.5% AB+ serum or medium alone for 20 min followed by PI 3-kinase assay as described under "Experimental Procedures." The upper rectangle shows phosphatidylinositol phosphate (PIP) spots, and the graph below shows the corresponding activities calculated as described in the legend to Fig. 5B. In A and B the values shown are the averages of two independent determinations obtained in separate experiments. The PI 3-kinase activities shown in C are the means ± S.E. of values obtained in three separate experiments. The autoradiograph shown in the upper portion of C is from one of the latter three experiments and is representative of results obtained in the two companion experiments.

LPS-induced Adherence Is Cytohesin-1-dependent-- Cytohesin-1 is an adaptor molecule that interacts specifically with the cytoplasmic tail of CD18 to increase cell adhesion to ICAM-1 (11). It is also known that binding of PtdIns-3,4,5-P3 to the pleckstrin homology domain of cytohesin-1 is required for activating cellular adhesion (12). Given that cytohesin-1 is not ubiquitously expressed (11), expression of this adaptor molecule in THP-1 cells was examined. Semiquantitative RT-PCR using primers for cytohesin-1 was carried out using total RNA of THP-1 cells. The results shown in Fig. 7 demonstrate that cytohesin-1 mRNA is expressed in both THP-1wt and THP-1rsv cells. An antisense strategy to inhibit cytohesin-1 expression was used to examine whether cytohesin-1 is involved in LPS-induced adherence. THP-1wt cells were incubated in the presence of antisense S-oligos spanning the cytohesin-1 translation initiation region (including the ATG initiation codon) and then assayed for adherence in response to LPS. As shown in Fig. 8A, treatment of cells with antisense S-oligo to cytohesin-1 mRNA significantly attentuated LPS-induced adherence in a concentration-dependent manner with maximal inhibition (72 ± 8%) at 5 µM. In contrast, at 5 µM of control, sense S-oligo, only a minimal effect on adherence was observed. This finding suggested a direct role of cytohesin-1 in the response of THP-1 cells to LPS. FACS analysis of cells exposed to fluorescein modified antisense S-oligo, in the same conditions used for unmodified S-oligos, revealed that THP-1 cells readily incorporated foreign DNA. However, a significant proportion of cells (24%) remained S-oligo-free (Fig. 8B). This finding may explain why antisense S-oligo treatment did not result in complete inhibition of LPS-induced adherence. Increasing the concentration of either S-oligos, LipofectAMINE, or both, to achieve a transfection rate approaching 100% resulted in toxicity thereby reducing the specificity of the antisense S-oligo treatment (data not shown).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Expression of cytohesin-1 mRNA in THP-1rsv and THP-1wt cells. Total RNA from exponentially growing cells was extracted, and RT-PCR was carried out for cytohesin-1 and actin as described under "Experimental Procedures." Lane A, THP-1wt; lane B, THP-1rsv. Negative controls consisting of no DNA and RNA without reverse transcriptase were included, and no signals were obtained (data not shown). Serial dilutions of input cDNA were examined to ensure that the amplification was in the linear range for the PCR reaction.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Cytohesin-1 antisense S-oligos inhibit LPS-induced adherence to ICAM-1. A, THP-1wt cells were incubated with various concentrations of S-oligos for 2 h at 37 °C in 250 µl of RPMI 1640 containing 2.5% LipofectAMINE. The medium was then adjusted to 1 ml and supplemented with 10% FCS, and culture was continued for 18 h. Cells were then washed and tested in the adhesion assay as described in the legend to Fig. 2. B, THP-1wt cells were incubated with 5 µM fluoresceinated-5' antisense S-oligo using the same conditions as for unmodified S-oligo. Cells were washed and analyzed by FACS as described in the legend to Fig. 1. The data shown in A are the means ± S.E. of values obtained in three independent experiments. Results in B represent one of two independent experiments with similar results. The histogram on the left in B represents cells incubated with medium alone (autofluorescence), and the histogram on the right corresponds to cells incubated with fluorescein-labeled, sense S-oligo.


    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

This study examined signaling events required for LPS-induced adherence. The system used involved a quantitative, microtiter adhesion assay, CD14 transfected THP1 cells, and immobilized sICAM-1. Adherence in this system was found to be dependent upon CD14 (Fig. 2). Experiments that examined competitive inhibition of LPS-induced adherence using mAbs to CD14, CD18, and CD11a (Fig. 3A) provided direct evidence that LPS-induced adherence to sICAM-1 involves a CD14 mediated signal leading to activation of cell surface expressed LFA-1. These findings are consistent with previous data showing that antibody cross-linking of cell surface CD14 induces LFA-1 activation (40). LPS effects on LFA-1 did not involve changes in the expression of CD18 or CD11a. This indicates that LPS-induced adhesion was related to increased affinity of LFA-1 for ICAM-1 rather than to increased expression of cell surface LFA-1. Such changes in the properties of LFA-1 are presumably mediated by a specific pathway of inside-out signaling initiated through CD14.

The requirement for PI 3-kinase activity in a variety of leukocyte functions, together with its apparent role in the adhesion of platelets (41), lymphocytes (42), and neutrophils (33), made this enzyme an attractive candidate for mediating signaling through CD14 for monocyte adhesion. This hypothesis was supported further by the finding that LPS induces the CD14-dependent association of an activated form PI 3-kinase with p53/p56lyn (20). The role of PI 3-kinase in LPS-induced adherence was examined using two different approaches. The first involved the use of two structurally unrelated PI 3-kinase inhibitors wortmannin and LY294002. LPS-induced adherence was attenuated by both of these agents (Fig. 4). The effects of wortmannin are considered to be relatively specific for PI 3-kinase at concentrations similar to those used in this study (50 nM, Fig. 4). However, the compound has been shown to inhibit phospholipase A2 with an IC50 similar to that reported previously for PI 3-kinase (43). On the other hand, the structurally unrelated compound, LY294002, has been shown to inhibit PI 3-kinase by a distinct mechanism (44). Moreover, LY294002 shows no inhibitory effects on other lipid kinases or on several protein kinases, including protein kinase C and mitogen-activated protein kinase (44). The findings that both compounds inhibited LPS-induced adherence, therefore, support the argument that PI 3-kinase is involved in the regulation of adherence in response to LPS. This conclusion is supported further by experiments in which a dominant negative mutant of PI 3-kinase (Delta p85) expressed in U937 cells completely abrogated LPS-induced adherence to sICAM-1 (Fig. 5B). It has been shown previously that incubation of monocytes with LPS activates PI 3-kinase, leading to increased cellular levels of PtdIns-3,4,5-P3 (20). Thus, the most likely mechanism for the attenuation of adherence by either wortmannin, LY294002, or Delta p85 is inhibition of the formation of PtdIns-3,4,5-P3.

It has been reported previously that the small G-protein Rho regulates PI 3-kinase activation in different cell systems (45-47). This finding suggested the possibility that LPS-induced adherence may be Rho-regulated and mediated by PI 3-kinase. In this report, a requirement for Rho in LPS-induced adherence was suggested by studies that used C. difficile toxin B, which specifically inhibits Rho family proteins (38, 48). Pretreatment of THP-1wt cells with toxin B for 30 min. attenuated LPS-induced adherence to sICAM-1 (Fig. 6, A and B). In contrast, PMA-induced adherence appeared to be mediated by a toxin B-insensitive pathway (Fig. 6, A and B). This dichotomy is consistent with reports showing that PMA-induced responses in a variety of cell types may be either resistant to Rho toxins or that inhibition of these responses requires prolonged periods of incubation with toxins (24 h and more) (49, 50). For example 8-24-h of pretreatment with botulinum C3 exoenzyme, another inhibitor of Rho family proteins, was required to attenuate PMA-induced, LFA-1/ICAM-1-dependent aggregation of the lymphoblastoid cell line JY (49). On the other hand, PMA-induced activation of phospholipase D in HEK-98 (human embryonic kidney) cells was resistant to treatment with C. difficile toxin B for as long as 24 h (50). In the present study, THP-1 cells were incubated with toxin B for up to a maximum of 3 h. Under these conditions it is clear that adherence induced by LPS was toxin-sensitive, whereas the response to PMA was markedly resistant.

The findings that both Rho and PI 3-kinase appeared to be essential for LPS-induced adherence raised the question as to whether they act independently or whether they are positioned together in a single signaling pathway. Fig. 6C shows that toxin B prevented activation of PI 3-kinase in LPS-stimulated THP-1wt cells, suggesting that Rho regulates this LPS response in monocytes. This observation is consistent with previous reports showing involvement of Rho in PI 3-kinase activation in other systems (45-47). Although we cannot completely eliminate the possibility of a direct, PI 3-kinase-independent role for Rho in regulating monocyte adherence, the data suggest that LPS triggers Rho-mediated activation of PI 3-kinase, leading to downstream effects on LFA-1 and monocyte adherence.

An important question arising from these observations is how PI 3-kinase activation modulates the properties of LFA-1. Recently, cytohesin-1 has been shown to interact with the cytoplasmic tail of CD18 (11). Cytohesin-1 contains a domain homologous to the yeast Sec7 gene product and a pleckstrin homology domain. The Sec7 domain binds to and regulates LFA-1 (11), and this process is positively regulated by the binding of the PI 3-kinase metabolite PtdIns-3,4,5-P3 to the cytohesin-1 pleckstrin homology domain (12). Because a suitable antibody to cytohesin-1 was not available, RT-PCR of THP-1 mRNA was used to examine whether cytohesin-1 is expressed in THP-1 cells. The results shown in Fig. 7 confirmed that the cytohesin-1 gene is transcribed under basal conditions. To directly address the role of cytohesin-1 in LPS-induced adherence, cytohesin-1-specific antisense oligonucleotides were used. To ensure maximal specificity of the antisense oligonucleotide, the sequence selected was from a region lacking significant homology with other sequenced human genes. The oligonucleotides were also phosphorothioate-modified to limit degradation and purified by high performance liquid chromatography to remove incomplete synthesis products. In addition fluorescein-modified antisense and FACS analysis were used to monitor oligonucleotide incorporation into cells. The finding that antisense treatment of THP-1 cells, but not treatment with sense oligonucleotide, significantly attenuated LPS-induced adherence to ICAM-1 (Fig. 8A) provided compelling evidence to suggest that cytohesin-1 plays an essential role in adherence induced by LPS. Of note, the proportion of cells that incorporated antisense-oligonucleotide (Fig. 8B) correlated closely with the fraction of cells that failed to adhere in response to LPS (Fig. 8A).

Taken together, the results presented are consistent with a model (Fig. 9) in which LPS binding to CD14 switches on the small G-protein Rho leading to activation of PI 3-kinase. This leads to increased monocyte adherence, dependent upon changes in the adhesive properties of LFA-1. The latter appears to involve the interaction of PtdIns-3,4,5-P3, cytohesin-1, and LFA-1.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 9.   LPS-induced, monocyte adherence to ICAM-1. Monocyte adhesion to ICAM-1 involves activated LFA-1 and the adaptor molecule cytohesin-1. The latter is believed to be dependent on PtdIns-3,4,5-P3 (PIP3). LPS binding to CD14 (1) engages the small G protein Rho (2) leading to activation of PI 3-kinase (3). PtdIns-3,4,5-P3 (4) binds to the pleckstrin homology (PH) domain of cytohesin-1, thereby modifying its interaction, through its Sec7 domain, with the cytoplasmic tail of CD18 (5). This leads to altered properties of LFA-1 (6) and to increased affinity for its counter receptor ICAM-1.


    ACKNOWLEDGEMENTS

We thank Dr. J. R. Woska, Jr. for sICAM-1, Dr. Glen Armstrong for toxin B, Dr. W. C. Van Voorhis for antibody to CD14, and Dr. R. Ulevitch for THP-1wt and THP-1rsv cells.

    FOOTNOTES

* This work was supported by Medical Research Council of Canada Grant MT-8633.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

parallel To whom correspondence should be addressed: Division of Infectious Diseases, University of British Columbia, Rm. 452D, 2733 Heather St., Vancouver, British Columbia V5Z 3J5, Canada. Tel.: 604-875-4011; Fax: 604-875-4013; E-mail: ethan{at}unixg.ubc.ca.

The abbreviations used are: LFA-1, leukocyte function-associated antigen-1; LPS, lipopolysaccharide; ICAM-1, intercellular adhesion molecule-1; sICAM-1, purified soluble, recombinant ICAM-1; THP-1wt, THP-1 cells transfected with CD14-cDNA; THP-1rsv, THP-1 cells transfected with vector alone; PI 3-kinase, phosphatidylinositol 3-kinase; PMA, phorbol 12-myristate 13-acetate; PtdIns-3, 4,5-P3, phosphatidylinositol 3,4,5-trisphosphate; HBSS, Hanks' balanced salt solution; Wp85alpha , wild-type bovine PI 3-kinase subunit p85; Delta p85alpha , alpha -chain, mutant bovine p85alpha ; MFI, mean fluorescence intensity; FCS, fetal calf serum; S-oligo, phosphorothioate modified oligonucleotide; FITC, fluorescein isothiocyanate; mAb, monoclonal antibody; BSA, bovine serum albumin; RT-PCR, reverse transcription-polymerase chain reaction; FACS, fluorescence-activated cell sorter.
    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Bevilacqua, M. P., Nelson, R. M., Mannori, G., and Cecconi, O. (1994) Annu. Rev. Med. 45, 361-378[CrossRef][Medline] [Order article via Infotrieve]
  2. Bevilacqua, M. P., Pober, J. S., Wheeler, M. E., Cotran, R. S., and Gimbrone, M. A., Jr. (1985) J. Clin. Invest. 76, 2003-2011[Medline] [Order article via Infotrieve]
  3. Wallis, W. J., Beatty, P. G., Ochs, H. D., and Harlan, J. M. (1985) J. Immunol. 135, 2323-2330[Abstract/Free Full Text]
  4. Dustin, M. L., and Springer, T. A. (1989) Nature 341, 619-623[CrossRef][Medline] [Order article via Infotrieve]
  5. Van Kooyk, Y., van de Wiel-van Kemenade, P., Weder, P., Kuijpers, T. W., and Figdor, C. G. (1989) Nature 342, 811-813[CrossRef][Medline] [Order article via Infotrieve]
  6. Springer, T. A. (1990) Nature 346, 425-434[CrossRef][Medline] [Order article via Infotrieve]
  7. Lub, M., Van Kooyk, Y., and Figdor, C. G. (1995) Immunol. Today 16, 479-483[CrossRef][Medline] [Order article via Infotrieve]
  8. Staunton, D. E., Marlin, S. D., Stratowa, C., Dustin, M. L., and Springer, T. A. (1988) Cell 52, 925-933[Medline] [Order article via Infotrieve]
  9. Lollo, B. A., Chan, K. W. H., Hanson, E. M., Moy, V. T., and Brian, A. A. (1993) J. Biol. Chem. 268, 21693-21700[Abstract/Free Full Text]
  10. Dustin, M. L., and Springer, T. A. (1991) Annu. Rev. Immunol. 9, 27-66[CrossRef][Medline] [Order article via Infotrieve]
  11. Kolanus, W., Nagel, W., Schiller, B., Zeitlmann, L., Godar, S., Stockinger, H., and Seed, B. (1996) Cell 86, 233-242[Medline] [Order article via Infotrieve]
  12. Klarlund, J. K., Guilherme, A., Holik, J. J., Virbasius, J. V., Chawla, A., and Czech, M. P. (1997) Science 275, 1927-1930[Abstract/Free Full Text]
  13. Haslett, C., Worthen, G. S., Giclas, P. C., Morrison, D. C., Henson, J. E., and Henson, P. M. (1997) Am. Rev. Respir. Dis. 136, 9-18
  14. Pohlman, T. H., Stanness, K. A., Beatty, P. G., Ochs, H. D., and Harlan, J. M. (1986) J. Immunol. 136, 4548-4553[Abstract/Free Full Text]
  15. Smedly, L. A., Tonnesen, M. G., Sandhaus, R. A., Haslett, C., Guthrie, L. A., Johnston, R. B., Jr., Henson, P. M., and Worthen, G. S. (1986) J. Clin. Invest. 77, 1233-1243[Medline] [Order article via Infotrieve]
  16. Owen, C. A., Campbell, E. J., and Stockley, R. A. (1992) J. Leukocyte Biol. 51, 400-408[Abstract]
  17. Schumann, R. R., Leong, S. R., Flaggs, G. W., Gray, P. W., Wright, S. D., Mathison, J. C., Tobias, P. S., and Ulevitch, R. J. (1990) Science 249, 1429-1431[Medline] [Order article via Infotrieve]
  18. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., and Mathison, J. C. (1990) Science 249, 1431-1433[Medline] [Order article via Infotrieve]
  19. Stefanová, I., Corcoran, M. L., Horak, E. M., Wahl, L. M., Bolen, J. B., and Horak, I. D. (1993) J. Biol. Chem. 268, 20725-20728[Abstract/Free Full Text]
  20. Herrera-Velit, P., and Reiner, N. E. (1996) J. Immunol. 156, 1157-1165[Abstract]
  21. Herrera-Velit, P., Knutson, K. L., and Reiner, N. E. (1997) J. Biol. Chem. 272, 16445-16452[Abstract/Free Full Text]
  22. Ward, S. G., June, C. H., and Olive, D. (1996) Immunol. Today 17, 187-197[CrossRef][Medline] [Order article via Infotrieve]
  23. Shimizu, Y., and Hunt, S. W., III (1996) Immunol. Today 17, 565-573[CrossRef][Medline] [Order article via Infotrieve]
  24. Hmama, Z., Mey, A., Normier, G., Binz, H., and Revillard, J. P. (1994) Infect. Immun. 62, 1520-1527[Abstract]
  25. Hmama, Z., Normier, G., Kouassi, E., Flacher, M., Binz, H., and Revillard, J. P. (1992) Immunobiology 186, 183-198[Medline] [Order article via Infotrieve]
  26. Hara, K., Yonezawa, K., Sakaue, H., Ando, A., Kotani, K., Kitamura, T., Kitamura, Y., Ueda, H., Stephens, L., Jackson, T. R., Hawkins, P. T., Dhand, R., Clark, A. E., Holman, G. D., Waterfield, M. D., and Kasuga, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7415-7419[Abstract]
  27. Nandan, D., and Reiner, N. E. (1997) J. Immunol 158, 1095-1101[Abstract]
  28. Liu, L., and Pohajdak, B. (1992) Biochim. Biophys. Acta 1132, 75-78[Medline] [Order article via Infotrieve]
  29. Liu, M. K., Herrera-Velit, P., Brownsey, R. W., and Reiner, N. E. (1994) J. Immunol. 153, 2642-2652[Abstract/Free Full Text]
  30. Sanchez-Madrid, F., Krensky, A. M., Ware, C. F., Robbins, E., Strominger, J. L., Burakoff, S. J., and Springer, T. A. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 7489-7493[Abstract]
  31. Smith, C. W., Rothlein, R., Hughes, B. J., Mariscalco, M. M., Rudloff, H. E., Schmalstieg, F. C., Anderson, D. C., and Speros, P. (1988) J. Clin. Invest. 82, 1746-1756[Medline] [Order article via Infotrieve]
  32. Philips, M. R., Buyon, J. P., Winchester, R., and Weissmann, G. (1988) J. Clin. Invest. 82, 495-501[Medline] [Order article via Infotrieve]
  33. Capodici, C., Hanft, S., Feoktistov, M., and Pillinger, M. H. (1998) J. Immunol. 160, 1901-1909[Abstract/Free Full Text]
  34. Kundra, R., and Kornfeld, S. (1998) J. Biol. Chem. 273, 3848-3853[Abstract/Free Full Text]
  35. Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., and Hall, A. (1992) Cell 70, 401-410[Medline] [Order article via Infotrieve]
  36. Laudanna, C., Campbell, J. J., and Butcher, E. C. (1996) Science 271, 981-983[Abstract]
  37. Laudanna, C., Campbell, J. J., and Butcher, E. C. (1997) J. Biol. Chem. 272, 24141-24144[Abstract/Free Full Text]
  38. Just, I., Fritz, G., Aktories, K., Giry, M., Popoff, M. R., Boquet, P., Hegenbarth, S., and von Eichel-Streiber, C. (1994) J. Biol. Chem. 269, 10706-10712[Abstract/Free Full Text]
  39. Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M., and Aktories, K. (1995) Nature 375, 500-503[CrossRef][Medline] [Order article via Infotrieve]
  40. Beekhuizen, H., Blokland, I., and Van Furth, R. (1993) J. Immunol. 150, 950-959[Abstract/Free Full Text]
  41. Toker, A., Bachelot, C., Chen, C. S., Falck, J. R., Hartwig, J. H., Cantley, L. C., and Kovacsovics, T. J. (1995) J. Biol. Chem. 270, 29525-29531[Abstract/Free Full Text]
  42. Shimizu, Y., Mobley, J. L., Finkelstein, L. D., and Chan, A. S. (1995) J. Cell Biol. 131, 1867-1880[Abstract]
  43. Cross, M. J., Stewart, A., Hodgkin, M. N., Kerr, D. J., and Wakelam, M. J. O. (1995) J. Biol. Chem. 270, 25352-25355[Abstract/Free Full Text]
  44. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) J. Biol. Chem. 269, 5241-5248[Abstract/Free Full Text]
  45. Zhang, J., King, W. G., Dillon, S., Hall, A., Feig, L., and Rittenhouse, S. E. (1993) J. Biol. Chem. 268, 22251-22254[Abstract/Free Full Text]
  46. Gómez, J., García, A., Borlado, L. R., Bonay, P., Martínez-A, C., Silva, A., Fresno, M., Carrera, A. C., von Eichel-Streiber, C., and Rebollo, A. (1997) J. Immunol. 158, 1516-1522[Abstract]
  47. Zheng, Y., Bagrodia, S., and Cerione, R. A. (1994) J. Biol. Chem. 269, 18727-18730[Abstract/Free Full Text]
  48. Just, I., Richter, H. P., Prepens, U., von Eichel-Streiber, C., and Aktories, K. (1994) J. Cell Sci. 107, 1653-1659[Abstract/Free Full Text]
  49. Tominaga, T., Sugie, K., Hirata, M., Morii, N., Fukata, J., Uchida, A., Imura, H., and Narumiya, S. (1993) J. Cell Biol. 120, 1529-1537[Abstract]
  50. Schmidt, M., Voß, M., Thiel, M., Bauers, B., Grannaß, A., Tapp, E., Cool, R. H., de Gunzburg, J., von Eichel-Streiber, C., and Jakobs, K. H. (1998) J. Biol. Chem. 273, 7413-7422[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.